Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,339.26
    -1,778.67 (-2.02%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Today’s Research Reports on VentriPoint Diagnostics, Cotinga Pharmaceuticals, Knight Therapeutics and CanniMed Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

VentriPoint Diagnostics Ltd.
https://rdinvesting.com/news/?ticker=VPT.V

Cotinga Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=COT.V

Knight Therapeutics Inc.
https://rdinvesting.com/news/?ticker=GUD.TO

CanniMed Therapeutics Inc.
https://rdinvesting.com/news/?ticker=CMED.TO

ADVERTISEMENT

VentriPoint Diagnostics' stock had no change Friday, to close the day at $0.30. The stock recorded a trading volume of 12,000 shares, which was below its three months average volume of 106,901 shares. In the last year, VentriPoint Diagnostics' shares have traded in a range of 0.17 - 0.42. The share price has gained 79.41% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.305 is greater than its 200-day moving average of $0.28.

Access RDI's VentriPoint Diagnostics Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=VPT.V

On Friday, shares of Cotinga Pharmaceuticals recorded a trading volume of 8,150 shares, which was below the three months average volume of 15,425 shares. The stock ended the day flat at 0.49. The share price has gained 68.97% from its 52 week low with a 52 week trading range of 0.29 - 3.90. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.44 is below its 200-day moving average of $0.85. Shares of Cotinga Pharmaceuticals have fallen approximately 55.45 percent year-to-date.

Access RDI's Cotinga Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=COT.V

Knight Therapeutics' stock moved 1.12% lower Friday, to close the day at $7.96. The stock recorded a trading volume of 35,240 shares, which was below its three months average volume of 166,471 shares. In the last year, Knight Therapeutics' shares have traded in a range of 7.38 - 10.75. The stock is currently trading 25.95% below its 52 week high. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.82 is below its 200-day moving average of $7.95. Shares of the company are trading at a Price to Earnings ratio of 66.33. Shares of Knight Therapeutics have fallen approximately 4.21 percent year-to-date.

Access RDI's Knight Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GUD.TO

On Friday, shares of CanniMed Therapeutics recorded a trading volume of 22,143 shares, which was below the three months average volume of 290,152 shares. The stock ended the day 2.16% lower at 29.00. The share price has gained 296.17% from its 52 week low with a 52 week trading range of 7.32 - 46.00. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $33.67 is greater than its 200-day moving average of $26.64. Shares of the company are trading at a Price to Earnings ratio of 202.80. Shares of CanniMed Therapeutics have gained approximately 28.60 percent year-to-date.

Access RDI's CanniMed Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CMED.TO

Our Actionable Research on VentriPoint Diagnostics Ltd. (TSXV :VPT.V), Cotinga Pharmaceuticals Inc. (TSXV :COT.V), Knight Therapeutics Inc. (TSX :GUD.TO) and CanniMed Therapeutics Inc. (TSX :CMED.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: RDInvesting.com